On March 7, 2022 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "we" or "us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases, reported the IMMX Milestone Day Event, to be held on April 5, 2022 (Press release, Immix Biopharma, MAR 7, 2022, View Source [SID1234609550]). At the Event, management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With conflict in Europe and attendant volatility in capital markets, we believe it is appropriate to discuss that ImmixBio not only continues to be on track to achieve clinical data milestones as planned with the funding we raised in our IPO, but also act on new opportunities presented," said Ilya Rachman, MD PhD, Chief Executive Officer of ImmixBio. "Each day we are advancing ImmixBio forward towards the milestones we have committed to our investors, stakeholders, and patients."

"We raised $24.2 million in total gross proceeds 3 months ago at the end of December including full exercise of the underwriters’ over-allotment option in connection with our IPO," said Gabriel Morris, Chief Financial Officer of ImmixBio. "With Dr. Rachman’s experience as a clinical investigator for approved therapies, we believe we are ideally positioned to take advantage of market uncertainty to accomplish milestones with increasing capital efficiency."